Your browser is no longer supported. Please, upgrade your browser.
ANIP ANI Pharmaceuticals, Inc. daily Stock Chart
ANIP [NASD]
ANI Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.70 Insider Own0.60% Shs Outstand11.97M Perf Week0.11%
Market Cap322.10M Forward P/E7.14 EPS next Y3.83 Insider Trans16.46% Shs Float9.51M Perf Month-3.26%
Income-20.30M PEG- EPS next Q0.89 Inst Own79.40% Short Float5.79% Perf Quarter-9.83%
Sales197.50M P/S1.63 EPS this Y-61.80% Inst Trans-1.63% Short Ratio7.40 Perf Half Y-31.72%
Book/sh15.99 P/B1.71 EPS next Y6.31% ROA-4.40% Target Price38.33 Perf Year-65.17%
Cash/sh2.35 P/C11.63 EPS next 5Y2.20% ROE-9.90% 52W Range25.23 - 80.87 Perf YTD-55.70%
Dividend- P/FCF7.37 EPS past 5Y-28.10% ROI4.80% 52W High-66.22% Beta1.29
Dividend %- Quick Ratio1.30 Sales past 5Y29.80% Gross Margin61.90% 52W Low8.28% ATR1.15
Employees338 Current Ratio2.00 Sales Q/Q-10.80% Oper. Margin-8.30% RSI (14)39.95 Volatility3.95% 3.67%
OptionableYes Debt/Eq0.99 EPS Q/Q-295.20% Profit Margin-10.30% Rel Volume0.77 Prev Close27.79
ShortableYes LT Debt/Eq0.93 EarningsAug 06 BMO Payout- Avg Volume74.29K Price27.32
Recom2.00 SMA20-5.50% SMA50-7.01% SMA200-27.69% Volume57,221 Change-1.69%
May-07-20Downgrade Cantor Fitzgerald Overweight → Neutral
Sep-12-19Initiated Guggenheim Buy
May-10-19Downgrade Raymond James Strong Buy → Outperform $73 → $82
Oct-16-17Reiterated Canaccord Genuity Buy $60 → $66
Jul-31-17Initiated Canaccord Genuity Buy $60
Feb-22-17Downgrade ROTH Capital Buy → Neutral
Jun-23-16Initiated Raymond James Strong Buy $68
May-24-16Downgrade Standpoint Research Buy → Hold
Nov-13-15Initiated Standpoint Research Buy $54
Sep-28-15Upgrade ROTH Capital Neutral → Buy $67 → $60
Aug-05-15Reiterated Oppenheimer Outperform $74 → $65
Aug-04-15Reiterated ROTH Capital Neutral $70 → $67
Jul-31-15Reiterated Oppenheimer Outperform $72 → $74
Jul-15-15Reiterated ROTH Capital Neutral $60 → $70
Jun-23-15Reiterated Oppenheimer Outperform $61 → $67
May-18-15Reiterated ROTH Capital Neutral $78 → $60
May-06-15Reiterated Oppenheimer Outperform $69 → $61
Apr-10-15Downgrade ROTH Capital Buy → Neutral $78
Feb-26-15Reiterated ROTH Capital Buy $65 → $78
Feb-18-15Reiterated Oppenheimer Outperform $58 → $69
Oct-28-20 12:32PM  
Sep-10-20 07:00PM  
Aug-06-20 08:35AM  
06:50AM  
06:45AM  
Aug-03-20 06:50AM  
Jul-30-20 06:50AM  
Jul-29-20 12:33PM  
Jul-08-20 07:38AM  
Jul-06-20 08:30AM  
Jul-04-20 08:54PM  
Jun-30-20 08:30AM  
Jun-14-20 11:38PM  
Jun-01-20 08:30AM  
May-09-20 08:21AM  
May-08-20 06:30PM  
May-07-20 09:55AM  
08:30AM  
May-01-20 11:50AM  
Apr-30-20 08:30AM  
Apr-29-20 08:30AM  
Apr-24-20 06:45AM  
Apr-14-20 08:30AM  
Apr-13-20 08:30AM  
Apr-02-20 08:30AM  
Mar-26-20 08:30AM  
Mar-24-20 08:30AM  
Mar-11-20 03:37PM  
Mar-10-20 06:40AM  
Mar-05-20 07:17AM  
Mar-02-20 08:30AM  
Feb-29-20 07:35AM  
Feb-27-20 10:05AM  
08:30AM  
Feb-24-20 12:45PM  
Feb-21-20 05:25AM  
Feb-20-20 08:30AM  
Feb-19-20 12:31PM  
Feb-12-20 08:30AM  
Jan-24-20 08:30AM  
Jan-16-20 08:30AM  
05:39AM  
Jan-14-20 08:30AM  
Jan-09-20 08:30AM  
Dec-19-19 10:09AM  
Dec-18-19 08:30AM  
Dec-11-19 01:55PM  
05:06AM  
Dec-04-19 09:21AM  
07:45AM  
Nov-26-19 08:30AM  
Nov-22-19 05:19PM  
Nov-11-19 06:25AM  
Nov-06-19 09:55AM  
08:30AM  
08:21AM  
Oct-31-19 08:30AM  
Oct-30-19 08:30AM  
Oct-29-19 10:33AM  
08:30AM  
Oct-28-19 04:14PM  
Oct-12-19 08:26AM  
Oct-11-19 12:18PM  
Oct-10-19 10:37AM  
Oct-09-19 09:09AM  
Oct-03-19 08:30AM  
Oct-02-19 08:30AM  
Sep-29-19 11:39AM  
Sep-12-19 06:57AM  
Sep-11-19 08:30AM  
Sep-05-19 06:43PM  
Aug-13-19 08:08AM  
Aug-07-19 01:23PM  
09:45AM  
08:30AM  
Jul-31-19 08:30AM  
Jul-30-19 10:38AM  
Jul-09-19 02:38PM  
Jun-27-19 04:11PM  
Jun-25-19 08:30AM  
Jun-20-19 10:30AM  
Jun-18-19 08:00AM  
Jun-12-19 08:30AM  
May-31-19 12:38PM  
May-16-19 09:00AM  
May-12-19 11:52AM  
May-10-19 10:23AM  
May-09-19 01:14PM  
08:39AM  
08:30AM  
May-02-19 08:30AM  
May-01-19 05:45PM  
Apr-30-19 09:00AM  
08:32AM  
Apr-29-19 08:05AM  
Apr-27-19 09:04AM  
Apr-26-19 11:11AM  
Apr-25-19 05:45PM  
09:31AM  
Apr-23-19 09:34AM  
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company offers pharmaceuticals for the treatment of breast cancer, hypertension, ventricular arrhythmias, stage D2 metastatic carcinoma of the prostate, depression, diarrhea, infections, vasomotor symptoms of menopause, pain caused by osteoarthritis and rheumatoid arthritis, epilepsy, arrhythmia, obsessive-compulsive disorder and social anxiety disorder, ulcerative colitis, salt and fluid retention, manic episodes of bipolar disorder, ulcerative colitis, proctosigmoiditis, ocular conditions, metastatic prostate cancer, arrhythmia, migraine headache, and enterocolitis caused by staphylococcus aureus. It also provides aspirin and extended-release dipyridamole; Cholestyramine, an adjunctive therapy to diet for the reduction of elevated serum cholesterol; Ezetimibe-Simvastatin to lower high cholesterol and triglyceride levels; Fenofibrate, a peroxisome proliferator receptor alpha activator; Hydrocortisone rectal cream for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Morphine Sulfate, an oral solution for acute and chronic pain management; Nimodipine to enhance neurological outcomes; and Terbutaline Sulfate for the prevention and reversal of bronchospasm. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Walsh Patrick DCHAIRMAN, INTERIM PRES. & CEOAug 10Buy30.7810,000307,79030,096Aug 12 04:18 PM
HAUGHEY THOMASDirectorMar 04Buy45.053,000135,15011,291Mar 05 06:01 PM
HAUGHEY THOMASDirectorMar 03Buy45.182,00090,3608,291Mar 05 06:01 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.